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Introduction {#s1}
============

Patients with symptoms, evidence of ischaemia, and no obstructive coronary artery disease (CAD) are prevalent and increasing in frequency.^[@EHV647C1]^ Such patients have disability, healthcare resource consumption, and costs similar to those with obstructive CAD.^[@EHV647C2],[@EHV647C3]^ Many have evidence for coronary microvascular dysfunction (CMD), which is associated with adverse cardiovascular events.^[@EHV647C4]^ Persistent symptoms are often atypical and a management challenge. Thus, there are many gaps in our knowledge about these patients related to their evaluation (invasive vs. non-invasive), mechanisms responsible for their symptoms and CMD, and treatment targets.

Late sodium current inhibition with ranolazine is effective for stable angina with obstructive CAD,^[@EHV647C8]^ and endorsed for such patients in the most recent ESC guidelines.^[@EHV647C16]^ Ranolazine inhibits the late sodium current in cardiomyocytes, decreasing Na^+^ and Ca^2+^ overload. During ischaemia, excess intracellular Ca^2+^ impairs myocyte relaxation facilitating increases in ventricular diastolic stiffness and further impaired perfusion. Ranolazine also promotes the switch from the inefficient fatty acid metabolism towards the oxygen-sparing glucose and lactate oxidation, further reducing oxygen consumption. Evidence to date, however, has not clearly demonstrated whether the anti-anginal effect is related to improved myocardial perfusion reserve. Furthermore, most CMD patients are women,^[@EHV647C17]^ yet pivotal trials with ranolazine^[@EHV647C8]^ contained few women and studied effort angina due to obstructive CAD.

Stress cardiac magnetic resonance perfusion imaging (CMRI) can non-invasively detect CMD,^[@EHV647C18]^ and is associated with disordered left ventricular (LV) diastolic function^[@EHV647C21]^ in CMD patients. A pilot trial suggested benefit of ranolazine in CMD subjects with typical angina.^[@EHV647C22]^

Accordingly, we conducted a trial in subjects with symptoms with no obstructive CAD, but evidence of CMD to mechanistically test whether symptoms are related to myocardial perfusion reserve index and can be influenced by late sodium current inhibition ([www.clinicaltrials.gov](www.clinicaltrials.gov), NCT01342029). The results should provide information to address some of the aforementioned knowledge gaps and direction for future studies in this enlarging population.

Methods {#s2}
=======

Patient population {#s2a}
------------------

Inclusion/exclusion criteria, study protocol, and list of investigators appear in [Supplementary material online, Online Exhibit A](#sup1){ref-type="supplementary-material"}. Briefly, we enrolled subjects with symptoms thought due to ischaemia, no obstructive CAD (\<50% epicardial coronary stenosis in all epicardial coronary arteries), and preserved LV ejection fraction, who had abnormal coronary reactivity testing (CRT) \[coronary flow reserve (CFR) \<2.5, or no dilation (≤0% change) with acetylcholine (Ach) response\], or abnormal stress CMRI \<2.0. Institutional Review Boards approved the study at the two sites and subjects gave written informed consent.

Study design {#s2b}
------------

To mechanistically test effects, we conducted a double-blind, placebo-controlled, crossover trial, with short-term (2 week) ranolazine--placebo exposure order randomly assigned. Obstructive CAD absence and CRT measures were verified \[Women\'s Ischemia Syndrome Evaluation (WISE) Angiography and Coronary Reactivity Cores\]. At baseline, subjects completed demographic/health history questionnaires, including the Seattle Angina Questionnaire (SAQ^[@EHV647C23]^ and SAQ-7),^[@EHV647C24]^ angina diary, Duke Activity Status Index (DASI),^[@EHV647C25]^ and general quality of life (QoL).^[@EHV647C26]^ Anti-anginal medications were unchanged. To maximize concurrent WISE recruitment, the study drug exposure was reduced from the pilot study^[@EHV647C22]^ 4--2 weeks followed by 2-week washout, and crossover to 2 weeks (see [Supplementary material online,](#sup1){ref-type="supplementary-material"}[Supplementary Data](#sup1){ref-type="supplementary-material"} and *Figure [1](#EHV647F1){ref-type="fig"}*). Ranolazine (Gilead Sciences, Foster City, CA, USA) was administered as 500 mg orally twice daily for 1-week and increased to 1000 mg twice daily for 1-week as tolerated (subjects taking verapamil or diltiazem maintained 500 mg b.i.d. of ranolazine or placebo). Treatment compliance was measured by pill count. Data were collected at baseline (SAQ) and at the end of each treatment period (SAQ, CMRI).

The angina and nitroglycerin diary,^[@EHV647C12]^ SF-36,^[@EHV647C26]^ MOS-116,^[@EHV647C27]^ and HIS-GWB Mental Health Battery^[@EHV647C28]^ were used as previously described.^[@EHV647C29]^

Cardiac magnetic resonance imaging {#s2c}
----------------------------------

The CMRI protocol (see Supplementary material online, Exhibit B) was performed (1.5 Tesla magnet, Siemens Sonata, Erlangen, Germany) with ECG-gating and phased array coil with 0.05 mmol/kg gadolinium first-pass perfusion three slice at rest, during pharmacological and cold-pressor stress.^[@EHV647C30]^ Myocardial scar was determined by late gadolinium enhancement (LGE) in a subset. Adenosine (140 μg/kg/min) or regadenoson (0.4 mg) if intolerant was consistent for periods. Cardiac magnetic resonance imaging was conducted under identical conditions and timing, dosing, and settings, ∼4-h after the morning study drug dose.

First-pass perfusion images were analysed using CAAS MRV CMRI analysis software Version 3.3 (Pie Medical Imaging B.V., Maastricht, the Netherlands). Software determined epicardial and endocardial contours of LV myocardium were manually corrected for MPRI intensity--time curves. Global sub-endocardial and sub-epicardial MPRI were calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope (higher is better myocardial perfusion reserve). The sub-endocardial and sub-epicardial layers were software determined as the inner and outer 50% wall thickness. These methods have high inter-study and observer reproducibility,^[@EHV647C31],[@EHV647C32]^ with best reproducibility in the mid-ventricle.^[@EHV647C18]^ An MPRI ≤1.8 is considered abnormal,^[@EHV647C20]^ and correlates with CRT^[@EHV647C20]^ and risk factors.^[@EHV647C33]^ Left ventricular mass and volumes were evaluated by manual tracing; papillary muscles were included in the LV mass/excluded from the LV volume. Volumetric diastolic filling was used to calculate early peak filling rate (PFR) and time to PFR (tPFR).^[@EHV647C21]^

Invasive coronary reactivity testing {#s2d}
------------------------------------

Clinically indicated invasive CRT measured coronary micro- and macro-vascular endothelial and non-endothelial-dependent function^[@EHV647C6],[@EHV647C34]^ was available in 87 subjects (62.5%). Coronary flow reserve was measured by Doppler flow-wire (FloWire^®^ Volcano, San Diego, CA, USA) following intracoronary (IC) adenosine injections, while graded IC Ach assessed endothelial function.

All measurements were made in the WISE Angiographic, CMRI, and CRT Core Labs masked to treatment period.

Statistical analysis {#s2e}
--------------------

Subjects were randomized at a 1:1 ratio and blocked by clinical site.^[@EHV647C35]^ Using a 2 × 2 crossover design, a sample size of 116 would achieve 90% power to detect a mean difference of 15 in SAQ score^[@EHV647C22]^ using a two-sided *t*-test at the 0.017 Holm--Bonferroni-corrected level of significance (HB), and standard deviation of 43.4 for paired difference in SAQ angina stability scores.^[@EHV647C22]^ Given the smaller standard deviations of the difference for the other two co-primary endpoints, the current trial was well powered for all the co-primary endpoints. A 10% attrition was assumed and target sample size was 134.

The analytic approach was a within-subjects comparison (paired) of the difference between baseline-treatment periods (SAQ, QoL) (a total of four measurements per subject, including two baselines and two treatment periods) or treatment periods (CMRI) (a total of two measurements per subject, including two treatment periods). The distribution of within-subjects differences was assessed to deploy appropriate statistical techniques. The primary approach was a standard paired *t*-test. Linear regression models were tested using treatment differences as the outcome. A stepwise procedure was used to choose the variables that were significantly associated with the outcomes. The overall type I error rate for the three co-primary outcome measures was controlled at 5% by the HB^[@EHV647C36]^ sequential procedure. Carry-over effects tested the interaction between treatment and period by comparing the mean within subject with means between the arms.^[@EHV647C37]^ Sub-group analyses included relevant clinical variables,^[@EHV647C15]^ prior ranolazine exposure, randomization sequence, site, adenosine vs. regadenoson, full vs. reduced ranolazine dose, prior myocardial infarction by history or CMRI-LGE, and qualifying CRT and CMRI variables. The significance level for outcomes other than the three co-primary endpoints was set to 0.05. A subject was included if they completed SAQ at baseline, SAQ, and CMRI for both treatment periods, and ≥50% of drug for both periods. Analyses were performed using SAS v9.3 (SAS Institute, Inc., Cary, NC, USA).

Study oversight {#s2f}
---------------

The study was investigator-initiated as an ancillary trial to the NHLBI-sponsored WISE, funded in part by Gilead Sciences, and used the WISE Data Safety Monitoring Committee. Statistical analysis was performed by the investigators independent of NHLBI and Gilead. The decision to submit for publication was made by the principal investigators who had access to all data after the last subject completed the study.

Results {#s3}
=======

Subject characteristics {#s3a}
-----------------------

Between 12 May 2011 and 10 August 2015, 435 subjects were screened, 393 eligible, 153 (96% women) enrolled, 10 (7%) subjects failed CMRI screening and 1 dropped out before randomization (*Table [1](#EHV647TB1){ref-type="table"}* and *Figure [1](#EHV647F1){ref-type="fig"}*). Among the 142 randomized, 8 (6%) dropped out (1 before receiving treatment, 5 while receiving ranolazine, 1 during placebo washout, and 1 while receiving placebo), and an additional 3 (2%) missed one or both treatment periods. This yielded 128 subjects with data from both periods available for analysis.

###### 

Baseline demographic and clinical variables

  Variables                                                             Mean ± SD, or absolute frequency (%)
  --------------------------------------------------------------------- --------------------------------------
  Age (years)                                                           55.2 ± 9.8
  Female                                                                96%
  BMI                                                                   29.3 ± 7.6
  \>30                                                                  50 (39.7%)
  Race (non-Caucasian)                                                  31 (24.2%)
  Tobacco use                                                           
  Current                                                               2 (1.6%)
  Former                                                                38 (29.7%)
  Never                                                                 88 (68.8%)
  History of hypertension                                               69 (53.9%)
  History of diabetes                                                   23 (18.0%)
  History of hyperlipidaemia                                            70 (54.7%)
  Family history of premature coronary artery disease                   83 (64.8%)
  Post-menopausal (*n* = 123)                                           100 (81.3%)
  Symptoms                                                              
   Typical Angina                                                       40 (31.3%)
   Shortness of Breath                                                  88 (68.8%)
   Palpitations                                                         53 (41.4%)
   Nausea                                                               40 (31.3%)
  Angina frequency (baseline SAQ angina frequency domain)               59.6 ± 26.9
  LV Ejection Fraction (%)                                              67.8 ± 7.7
  Qualifying CMRI (*n* = 86)^a^                                         
   Global myocardial perfusion reserve index (MPRI) \<2 (*n* = 67)^b^   1.6 ± 0.3
  Qualifying CRT (*n* = 87)^a^                                          
   LV end-diastolic filling pressure (LVEDP) (mmHg) (*n* = 74)          14.8 ± 5.1
   Qualifying CFR \<2.5 (*n* = 35)^b^                                   2.2 ± 0.2
   Qualifying Ach response \<0%^b^ (*n* = 36)                           −0.6 ± 15.6
   Beta-blockers                                                        54 (42.2%)
   Calcium current blockers; non-dihydropyridine                        29 (22.7%); 7 (24%)
   Angiotensin-converting enzyme inhibitors                             27 (21.1%)
   Angiotensin receptor vlockers                                        13 (10.2%)
   Nitrates                                                             50 (39.1%)
   Statins                                                              74 (57.8%)
   Hormone replacement therapy                                          16 (12.5%)

Ach, acetylcholine; BSA, body surface area; BMI, body mass index; CFR, coronary flow reserve; CMRI, cardiac magnetic resonance imaging; CRT, coronary reactivity testing; MPRI, myocardial perfusion reserve index; LV, left ventricular; SAQ, Seattle Angina Questionnaire.

^a^Subjects could have both CRT and CMRI.

^b^Subjects could have CMRI and CFR and Ach qualifiers.

![Study subject enrolment, screening, randomization and completion flow diagram. Treatment period 1 and 2: randomized to sequence of ranolazine first followed by crossover to placebo, or vice-versa.](ehv64701){#EHV647F1}

Many subjects were receiving beta-blockers, angiotensin-converting enzyme inhibitors, and statins. Despite anti-anginal therapy, all subjects had symptoms thought by their physicians to represent ischaemia although only 31% had typical angina. Among the 98 subjects with WISE baseline CMRI, 11% had myocardial scar by LGE (7-sub-endocardial or transmural, 3-mid-myocardial or epicardial or mixed, and 1-indeterminate), 69% had MPRI ≤1.8. Among the 87 subjects with baseline CRT, 38% had a CFR of \<2.5. Systolic and diastolic blood pressures were 123 ± 18 and 72 ± 12 mmHg, respectively.

Compliance and safety {#s3b}
---------------------

Overall compliance was 97%, while 21% (ranolazine) and 14% (placebo) subjects reduced to the 500 mg twice daily dosing for side-effects. Serious adverse events during the ranolazine period occurred in five patients \[hospitalization for NSTEMI (1); bronchospasm (1); chest pain, dizziness, and pre-syncope (2); and syncope (1)\], during the washout periods were hospitalization for chest pain (ranolazine washout, 1 patient) and bradycardia (placebo washout, 1 patient), and 0 during the placebo. Non-serious adverse events during ranolazine occurred in seven subjects---nausea and dizziness (3), arm shaking (1), back pain (1), renal abnormality (1), and throat swelling (1); in six subjects during placebo---chest pain (3), throat swelling (1), cough (1), and sinus infection (1); and in two subjects during washout---chest pain (1) and rectocele (1).

Angina, QoL, haemodynamics, and CMRI results {#s3c}
--------------------------------------------

None of the primary outcomes, other SAQ subscales, or angina or nitroglycerin use diary improved during ranolazine vs.. placebo (*Table [2](#EHV647TB2){ref-type="table"}*). Due to a higher variance in the baseline-treatment comparison, we also directly compared treatment periods^[@EHV647C14]^ and observed improved SAQ angina stability (7.23 ± 37.54, *P* = 0.03) and SAQ-7 (1.94 ± 12.90, *P* = 0.09) (neither significant at the 0.017 level). QoL depression improved during ranolazine (*P* = 0.0091) (*Table [2](#EHV647TB2){ref-type="table"}*). Results did not differ by menopausal status, or by excluding men. Mixed modelling in the entire cohort with treatment data demonstrated similar results.

###### 

Seattle Angina Questionnaire (SAQ), angina diary, functional capacity and quality of life (QoL), haemodynamic, myocardial perfusion reserve and diastolic filling treatment effect

                               Ranolazine   Placebo   Treatment change^a^                                                         
  ---------------------------- ------------ --------- --------------------- -------- ------- ----- ------- ---------------- ----- -------------
  SAQ                                                                                                                             
   Physical limitation         68.09        23.34     123                   66.70    23.34   120   −0.22   (−3.23, 2.79)    114   0.89
   Angina stability^b^         58.40        26.11     128                   51.17    27.68   128   5.12    (−3.51, 13.75)   127   0.24
   Angina frequency ^b^        63.91        26.09     128                   62.73    25.95   128   0.08    (−4.18, 4.34)    128   0.97
   Treatment satisfaction      74.16        21.23     127                   74.17    21.08   128   −0.48   (−3.98, 3.03)    127   0.79
   QoL                         56.05        23.09     128                   54.17    23.31   128   0.91    (−2.44, 4.27)    128   0.59
   SAQ overall                 62.49        19.32     128                   60.97    20.11   128                                  
  SAQ-7                                                                                                                           
   Physical limitation         71.67        24.18     124                   70.15    25.03   122                                  
   Angina frequency            63.91        26.09     128                   62.73    25.95   128                                  
   QoL                         55.76        27.97     128                   52.83    28.59   128                                  
   SAQ-7 overall^b^            63.54        21.09     128                   61.60    22.32   128   1.31    (−1.56, 4.17)    128   0.37
  Angina diary                                                                                                                    
   Angina episode              4.78         8.20      128                   4.88     7.75    128   −0.10   (−0.94, 0.73)    128   0.81
   NTG usage                   2.48         10.16     128                   2.62     11.18   128   −0.13   (−1.0, 0.74)     128   0.76
  SF-36                                                                                                                           
   Energy/fatigue              47.49        20.93     128                   46.45    20.43   128   1.40    (−2.27, 5.07)    119   0.45
   Emotional                   70.12        17.14     128                   68.28    16.97   128   2.82    (−0.56, 6.19)    119   0.10
  MOS-116                                                                                                                         
   Moody                       5.09         1.05      127                   4.92     1.19    128   0.14    (−0.12, 0.41)    118   0.28
   Low spirits                 5.12         1.08      127                   5.05     1.13    128   0.10    (−0.12, 0.32)    118   0.36
  HIS-GWB                                                                                                                         
   Depressed                   4.39         0.74      127                   4.27     0.87    128   0.20    (0.05, 0.36)     118   **0.009**
   Strain                      4.28         1.41      127                   4.20     1.44    128   0.11    (−0.20, 0.42)    118   0.49
   DASI score                  6.35         4.83      128                   6.20     5.05    128   0.31    (−0.58, 1.21)    128   0.49
  Pharmacological stress                                                                                                          
   HR (b.p.m.)                 95.17        13.50     128                   98.73    14.15   128   −3.55   (−4.99, −2.12)   128   **\<0.001**
   SBP (mmHg)                  127.2        21.60     129                   127.3    20.9    128   −0.56   (−3.93, 3.10)    129   0.75
   DBP (mmHg)                  60.17        16.52     129                   60.32    16.57   128   −0.49   (−3.23, 2.52)    129   0.73
   Stress RPP                  12 082       2707      128                   12 611   2796    128   −523    (−901, −97)      128   0.010
   Global MPRI                 1.98         0.46      128                   1.96     0.42    125   0.01    (−0.08, 0.09)    125   0.88
   MPRI mid--sub-endocardial   1.83         0.48      127                   1.77     0.38    124   0.06    (−0.04, 0.15)    124   0.23
  Diastolic filling                                                                                                               
   PFR (mL/s)                  333.3        105.9     127                   328.8    97.1    128   4.3     (−9.05, 17.71)   127   0.52
   tPFR (ms)                   163.9        45.3      127                   157.4    37.7    128   6.6     (−1.13, 14.33)   127   0.09

DASI, Duke Activity Status Index \[in metabolic equivalents (METS)\]; HIS-GWB Mental Health Battery; HR, heart rate; MOS 116, Medical Outcomes Study; MPRI, myocardial perfusion reserve index; MPRI-mid, mid-ventricular MPRI; mL, milliliter; NTG, nitroglycerin; PFR, peak filling rate; Pharmacologic Stress, adenosine or regadenoson infusion; QoL, quality of life; RPP, rate-pressure product; SAQ, Seattle Angina Questionnaire; ms, milliseconds; SF-36, MOS-36-Item Short-Form Health Survey; tPFR, time to peak filling rate.

^a^The SAQ, QoL, and DASI were measured pre- and post-treatment for both periods. All other outcomes were measured only post-treatment. Treatment change for SAQ, QoL, and DASI are the difference ranolazine-placebo in post- to pre-treatment changes.

^b^The HB critical levels were used for testing the three co-primary endpoints.

Overall, CMRI was interpretable in 127 pharmacological and 126 cold-pressor stress tests. We observed significantly lower pharmacological stress mean heart rate (HR) and rate-pressure product (RPP) during ranolazine vs. placebo (*Table [2](#EHV647TB2){ref-type="table"}*), but otherwise no haemodynamic differences. Pharmacological stress MPRI did not significantly improve with ranolozine vs. placebo (*Table [2](#EHV647TB2){ref-type="table"}*), nor did cold pressor (data not shown), or HR-corrected pharmacological stress MPRI (mid-ventricular global 2.06 ± 0.53 vs. 2.0 ± 0.42, *P* = 0.15) or mid-ventricular sub-endocardial (1.83 ± 0.48 vs. 1.77 ± 0.38, *P* = 0.18). Because myocardial flow reserve can be confounded by resting flow due to dependency on myocardial workload, we further corrected the resting MPRI with RPP and found similar results. Diastolic filling rates were similar for PFR with a trend towards higher tPFR (*P* = 0.09) on ranolazine vs. placebo (*Table [2](#EHV647TB2){ref-type="table"}*).

The change in SAQ-7 directly correlated with the change in MPRI (correlation 0.25, *P* = 0.005). In a multiple linear regression analysis, the MPRI-midventricular change differed by site and prior MI, adjusted for body mass index (BMI), and SAQ QoL change (*P* = 0.008). All of the angina variables were tried in the model. Two SAQ variables could enter into the models singly, but not at the same time: SAQ QoL and SAQ-7. Each of these had similar associations with the MPRI variables, but QoL has slightly better model fit statistics. The treatment difference in the QoL-depressed question had a significant positive association when added to the model for global mid-ventricular MPRI (*P* = 0.024), but was not significant for sub-endo or sub-epi mid-ventricular MPRI (*P* = 0.058 and *P* = 0.075, respectively). Modelling result demonstrated that as the estimated MPRI mid-ventricular change increased, SAQ QoL change increased, adjusted for BMI, prior MI and site (*P* = 0.004) (*Figure [2](#EHV647F2){ref-type="fig"}A*). Similar results were observed with mid-ventricular sub-endocardial MPRI (*P* = 0.003) (*Figure [2](#EHV647F2){ref-type="fig"}B*).

![Mid-ventricular and mid-ventricular sub-endocardial myocardial perfusion reserve index change vs. Seattle Angina Questionnaire quality of life change (ranolazine vs. placebo) model. The observed change in mid-ventricular myocardial perfusion reserve index (*A*) and mid-ventricular sub-endocardial myocardial perfusion reserve index (*B*) are plotted against the observed differences in treatment change for Seattle Angina Questionnaire quality of life with a line depicting a simple linear regression. The Pearson correlation and standard error (*r*, SEE) for this association are shown with the *P*-value for the test against zero correlation. The multiple regression described in the results showed that as myocardial perfusion reserve index--mid-ventricular change increased, Seattle Angina Questionnaire quality of life change increased, adjusted for body mass index, prior myocardial infarction and site (*P* = 0.005) with a similar model results for myocardial perfusion reserve index--mid-sub-endocardial change and Seattle Angina Questionnaire quality of life change (*P* = 0.005). Other variables tested that were not selected by the model include: pharmacological stress heart rate change, age, body mass index, site, history of hypertension, history of diabetes, prior ranolazine use, gender, left ventricular mass, end-diastolic volume, quality of life depressed change, had menopausal symptoms, baseline Seattle Angina Questionnaire angina frequency, Seattle Angina Questionnaire change (each of the five subdomains), adenosine vs. regadenson, and ranolazine dose level.](ehv64702){#EHV647F2}

Sub-group CRT analysis of the subjects using a clinically significant threshold of CFR \<2.5^[@EHV647C34]^ had higher global (ANOVA, *P* = 0.038) and mid-ventricular MPRI improvement during ranolazine compared with CFR 2.5--3 and above 3 (ANOVA, *P* = 0.014, *Figure [3](#EHV647F3){ref-type="fig"}*). Among subjects with CFR \<2.5, the treatment difference for SAQ angina frequency and SAQ-7 change was higher during ranolazine than placebo (paired *t*-test 9.43 ± 24.13, *P* = 0.027 and 6.62 ± 18.46, 0.041, respectively). Sub-group analysis according to typical vs. non-typical angina was negative; however, subjects with prior MI (*n* = 10) had higher global (0.30, *P* = 0.047) and sub-epicardial MPRI (0.32, *P* = 0.027) during ranolazine vs. placebo.

![Myocardial perfusion reserve index change according to qualifying coronary flow reserve in the subset of subjects with invasive coronary reactivity testing. Among subjects with qualifying coronary reactivity testing available coronary flow reserve and both period myocardial perfusion reserve index (*n* = 78), lower coronary flow reserve had significantly greater mid-ventricular myocardial perfusion reserve index change on ranolazine vs. placebo (*P* = 0.014). A higher myocardial perfusion reserve index number indicates better myocardial perfusion reserve.](ehv64703){#EHV647F3}

Discussion {#s4}
==========

In this short-term mechanistic trial, an anti-anginal agent effective for effort angina in patients with obstructive CAD, late Na current blockade with ranolazine, did not generally improve symptoms, myocardial perfusion reserve index, or diastolic filling in symptomatic subjects with no obstructive CAD but evidence of CMD. These findings suggest that short-term late sodium current inhibition with ranolazine is not generally effective for symptoms in this novel population. However, changes in angina and myocardial perfusion reserve index were directly related, indicating that symptoms are related to ischaemia in this population, supporting the case that therapies with the potential to improve ischaemia should be tested. Myocardial perfusion reserve index improved in sub-group of subjects with lower baseline CFR, consistent with prior study findings.^[@EHV647C42],[@EHV647C43]^

Invasively determined CRT is perhaps a more rigorous determination of CFR and comparable with PET.^[@EHV647C20],[@EHV647C38],[@EHV647C39]^ Among the entire cohort, slightly more than half underwent a clinically indicated invasive CRT, and 38% had low CFR \<2.5. Our result suggests that late sodium current inhibition with ranolazine may beneficially improve angina and myocardial perfusion reserve index in such a rigorously defined CMD population with more severe CMD. This result suggests that subjects with more severe CMD may benefit and should be included in future trials testing strategies to improve ischaemic morbidity and mortality.

Interestingly, stress HR and RPP on ranolazine was ∼4 b.p.m. lower vs. peak stress HR during placebo. Stress HR is an important determinant of myocardial oxygen demand, while pharmacological stress predominantly alters myocardial oxygen supply via arteriolar dilation (both coronary and systemic), the HR increase is mediated by reflex increases in beta-adrenegic activity. Furthermore, we observed a lower RPP during pharmacological stress on ranolazine vs. placebo supporting the suggestion that myocardial oxygen demand was lower during stress on ranolazine. To our knowledge, this is the first description of such an effect of ranolazine in humans. The pharmacological basis for our finding is suggested from experimental studies which have shown attenuated ranolazine dose-dependent isoproterenol increases in HR (beta~1~ receptor) and decreases in blood pressure (beta~2~ receptor) in rat and conscious dog models^[@EHV647C40],[@EHV647C41]^ and also supported by beta-adrenergic receptor binding data.^[@EHV647C41]^ The results indicate that ranolazine has a weak effect to antagonize beta-adrenergic receptors during stress. A minority of our subjects were on beta-blockers or non-dihydropyridine calcium current blockers, although these and the other anti-anginal medications were withdrawn for the stress testing. This HR effect also contributed to a small reduction in RPP supporting the suggestion that myocardial oxygen demand during stress was somewhat lower at the same MPRI. We may have observed different myocardial perfusion reserve and symptom responses if had we used exercise testing, as in previous ranolazine trials.^[@EHV647C8]^

Our current results differ from the pilot study^[@EHV647C22]^ used to design this CMD mechanistic trial. The current subjects had a much lower prevalence of typical or 'effort angina' (31 vs. 95%, respectively), which may explain the lack of anti-anginal benefit measured by the SAQ in the current results. Current subjects were also more obese (BMI 29.3 ± 7.5 vs. 25.6 ± 3.8, respectively), which may have impacted drug distribution and effect. While baseline SAQ scores were comparable, our pre-specified analysis plan compared baseline-treatment SAQ scores (a more conservative measure), vs. direct comparison of treatment periods in prior studies.^[@EHV647C22],[@EHV647C42]^ Qualifying myocardial perfusion reserve was higher (better) in the current cohort vs. our pilot (overall CMRI MPRI 1.8 ± 0.5 vs. 1.40 ± 0.43, respectively). While we did not have pilot measures of diastolic filling, LV end-diastolic pressure in CRT was comparable in the current and pilot (14.8 ± 5.1 vs. 14.71 ± 5 mmHg, respectively).

Our current results are also not consistent with two recent, but smaller studies in subjects with no obstructive CAD and CFR assessed by transthoracic Doppler. One studied 58 patients (only 19 women), with angina and abnormal myocardial perfusion, in a double-blind, placebo-controlled parallel trial of ranolazine 500 mg twice daily or placebo for 8-weeks. Ranolazine increased CFR and most SAQ domains vs. placebo.^[@EHV647C42]^ Another studied 46 patients with effort angina, abnormal exercise tests, CFR \<2.5 and persistent symptoms on anti-anginal agents, randomized to ranolazine (*n* = 15: 12 women, 375 mg twice daily), ivabradine or placebo (*n* = 15: 12 women) for 4-weeks. Ranolazine improved the SAQ vs. placebo and achieved better results vs. ivabradine: exercise time to 1-mm ST-segment depression and duration.^[@EHV647C43]^ More men, more typical effort angina, use of exercise testing, direct treatment period SAQ comparison, use of directly-measured CFR, and more severe CMD likely contributed to these different results.

Women comprised 96% of our population, precluding conclusions regarding response in men. Pivotal chronic angina trials with ranolazine were comprised mostly of men (∼75%).^[@EHV647C8]^ One was designed to determine dose--response and efficacy and found improvement in exercise time with doses used in the current trial, without suggestion of differential effects among men vs. women.^[@EHV647C8]^ Another found that ranolazine had similar angina and nitroglycerine use in women as in men, although less improvement on exercise testing-related angina.^[@EHV647C9]^ Importantly, subjects in these prior ranolazine trials had effort angina due to obstructive CAD.

Study limitations {#s5}
=================

Although the largest study to date in subjects with no obstructive CAD but CMD, our study by design was a mechanistic trial. Its strengths include a rigorous crossover design, use of validated measures and core laboratories, and CMRI and CRT evaluation. Limitations include a short-term 2-week exposure to ranolazine, although exposure duration was the same as a prior trial.^[@EHV647C10]^ Also, by design, only a subset qualified by clinically ordered CRT, and these subjects may have had lower CFR than those who qualified by CMRI, raising the possibility that more severe CMD explained the beneficial ranolazine response observed in this sub-group. The CFR analysis suggesting this concept is a sub-group, and therefore underpowered with a wide standard deviation, although significant and consistent with prior CFR studies. Use of angina diaries for angina is often limited by inappropriate input of multiple entries in a single sitting (so-called hoarding) and low compliance (as low as 11%).^[@EHV647C44]^ While we used objectively assessed MPRI, a validated quantitative myocardial perfusion reserve method, MPRI is based on the relative upslopes of arrival of myocardial contrast at stress and rest, which correlates with, but is not a direct measure of, CFR. Our future CMRI work will use our newly developed radial imaging and absolute CFR computation.^[@EHV647C45]^ The use of diastolic filling as a measure of diastolic function is a limitation as new approaches including tissue tagging acquisition,^[@EHV647C21]^ and post-processing diastolic function software^[@EHV647C46]^ appear to be improved measures; prior work has shown that ranolazine improves LV diastolic function.^[@EHV647C47],[@EHV647C48]^ The SAQ, used and validated among predominantly elderly men from a Veterans Administration hospital with effort angina due to obstructive CAD, may not measure the atypical 'angina-equivalents' such as shortness of breath, fatigue, indigestion, and weakness in this predominantly female population. Indeed, other symptoms may have completely different causes, including dyspnoea can be explained by obesity and palpitations are a frequent component of the post-menopausal syndrome. Furthermore, we modified the SAQ to a 2-week period to fit the protocol. Finally, we used selected SF-36, MOS-166, and HIS-GWB QoL variables, which may be less reliable than the full measures; however, the practice of using selected general QoL measures as part of lengthy batteries of questionnaires assessing disease-specific QoL is common.^[@EHV647C29]^

Conclusions {#s6}
===========

In this mechanistic trial, short-term late Na current blockade (ranolazine) effective for effort angina in patients with obstructive CAD did not significantly improve symptoms or myocardial perfusion reserve index in subjects with no obstructive CAD but evidence of CMD. This suggests that short-term late sodium current inhibition is not generally effective for SAQ angina in this novel population. Changes in the SAQ and myocardial perfusion reserve index were directly related, indicating that symptoms are related to myocardial perfusion reserve, supporting the notion that strategies to improve ischaemia should be tested in these subjects.
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